NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/XBIT.
Investigation Details
On December 23, 2024, XBiotech announced that it was pausing the phase 2 rheumatoid arthritis program for its drug candidate, Natrunix. According to the company, the program was paused due to its failure to meet the primary endpoint, and it suffered from "substantial irregularities that make unequivocal interpretation of the findings difficult." Following this news, XBiotech stock dropped, damaging investors.
What’s Next?
If you are aware of any facts relating to this investigation or purchased XBiotech securities, you can assist this investigation by visiting the firm’s site: bgandg.com/XBIT. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_462059903/2457/2025-01-21T10:01:47